Autoantibodies in Patients With Vitiligo

Brostoff, Jonathan; Bor, Simon; Feiwel, M

doi:10.1016/s0140-6736(69)91421-4

Cited by 106 publications

(35 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Circulating ANAs were observed in the literature in rates ranging from 2.5 to 33.3% (table 4) [9,12,18,21,23,24,25,26,27,28]. We detected a rate of ANA positivity of 16.8%, which is consistent with previous reports.…”

Section: Discussionsupporting

confidence: 92%

“…We detected a rate of ANA positivity of 16.8%, which is consistent with previous reports. In studies including a control group, no difference between vitiligo patients and controls was noticed [9,13,24,25,26]. In our sample, none of the patients' clinical and demographic variables considered was statistically associated with the presence of ANAs.…”

Section: Discussioncontrasting

confidence: 64%

See 1 more Smart Citation

Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study

et al. 2014

View full text Add to dashboard Cite

Background: Autoimmune comorbidities and circulating autoantibodies have been observed in vitiligo patients, but differences in rate are present according to countries in which the studies were performed, perhaps owing to ethnic diversities or different trigger factors. Objective: To estimate the prevalence of circulating autoantibodies and overt autoimmune diseases in a fairly large sample of Italian vitiligo patients. Methods: 175 outpatients affected by vitiligo and referred to nine dermatological centers were included in the study. Patients were offered routine blood test, serological testing for thyroid function and search for autoantibodies. Results: At least one circulating autoantibody was detected in 61 (41.8%) of 146 subjects who underwent laboratory tests. Anti-thyroperoxidase (25.6%), anti-thyroglobulin (23.4%), antinuclear antibodies (16.8%) and anti-gastric parietal cell antibodies (7.8%) were the most noticed autoantibodies. 74 (41.5%) autoimmune comorbidities, mainly autoimmune thyroiditis (37%), were reported. Conclusion: The prevalence of autoimmune comorbidities and circulating autoantibodies in this study was in agreement with other surveys conducted on Caucasian patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 64%

Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Vitiligo has been reported to be associated with organ-specific autoimmune diseases [1], Patients with vitiligo without overt au toimmune disease have an increased inci dence of organ-specific autoantibodies [2,3], The role of these autoantibodies is still un clear.…”

Section: Introductionmentioning

confidence: 99%

Incidence and Significance of Organ-Specific Autoimmune Disorders (Clinical, Latent or only Autoantibodies) in Patients with Vitiligo

Betterle

Caretto

A³

et al. 1985

Dermatology

View full text Add to dashboard Cite

The frequency of autoimmune disorders was determined in 373 vitiligo patients and in controls matched for sex, age and race. Vitiligo patients had an increased frequency of clinical autoimmune diseases of thyroid (7.5%), stomach (0.8%), parathyroid (1%), adrenal gland (1.3%). Vitiligo patients, without clinical signs of overt autoimmune diseases, also had a statistically significant increase in the frequency of gastric parietal cell (p < 0.001), thyroid microsomal (p < 0.05) and adrenal autoantibodies (p < 0.05). This increased incidence of autoimmune manifestations was correlated with the duration of vitiligo. Furthermore in 94% of the patients with parietal cell autoantibodies a gastric biopsy showed atrophic gastritis. In addition, in 48% of the patients with thyroid microsomal autoantibodies and in 2 out of 6 patients with adrenal autoantibodies without overt diseases at the beginning of the study, the functional investigation of the target organs during the follow-up allowed the detection of the presence or that of the subsequent development of clinical or subclinical dysfunction.

show abstract

“…Another indication that vitiligo may be an autoimmune disease is the fact that antibodies to melanocyte-associated antigens have been found in patients with vitiligo and correlate with disease activity. 3,4 Involvement of cellular immunity has been considered because T lymphocytes and macrophages in perilesional skin have been reported frequently. 5,6 Topical corticosteroids can be effective in the treatment of vitiligo.…”

mentioning

confidence: 99%

Left-Right Comparison Study of the Combination of Fluticasone Propionate and UV-A vs Either Fluticasone Propionate or UV-A Alone for the Long-term Treatment of Vitiligo

Westerhof¹,

Nieuweboer‐Krobotova²,

Mulder³

et al. 1999

Arch Dermatol

101

View full text Add to dashboard Cite

Autoantibodies in Patients With Vitiligo

Cited by 106 publications

References 4 publications

Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study

Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study

Incidence and Significance of Organ-Specific Autoimmune Disorders (Clinical, Latent or only Autoantibodies) in Patients with Vitiligo

Left-Right Comparison Study of the Combination of Fluticasone Propionate and UV-A vs Either Fluticasone Propionate or UV-A Alone for the Long-term Treatment of Vitiligo

Contact Info

Product

Resources

About